• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无痴呆帕金森病患者中淀粉样蛋白正电子发射断层扫描阳性的极低患病率

Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia.

作者信息

Mashima Kyoko, Ito Daisuke, Kameyama Masashi, Osada Takashi, Tabuchi Hajime, Nihei Yoshihiro, Yoshizaki Takahito, Noguchi Eri, Tanikawa Mariko, Iizuka Takashi, Date Yugaku, Ogata Yuji, Nakahara Tadaki, Iwabuchi Yu, Jinzaki Masahiro, Murakami Koji, Suzuki Norihiro

机构信息

Department of Neurology, Keio University School of Medicine, Tokyo, Germany.

出版信息

Eur Neurol. 2017;77(5-6):231-237. doi: 10.1159/000464322. Epub 2017 Mar 11.

DOI:10.1159/000464322
PMID:28285306
Abstract

BACKGROUND

Most cases of dementia with Lewy bodies (DLB) show Alzheimer's disease pathology-like senile plaques and neurofibrillary tangles. Several studies have also revealed a high prevalence of positive amyloid imaging with positron emission tomography (PET) in DLB and moderate prevalence in Parkinson's disease (PD) with dementia. However, it remains unclear in PD without dementia as to when the brain β amyloid (Aβ) burden begins and progresses. Our study aimed to determine the prevalence of Aβ deposition in PD without dementia using amyloid PET.

METHODS

This was a cross-sectional study on 33 patients with PD without dementia, of whom 21 had normal cognition and 12 met the criteria for PD-mild cognitive impairment. All subjects underwent neuropsychological assessment and [18F] florbetaben (FBB) PET.

RESULTS

All subjects had Lewy body-related disorders, displaying a significantly reduced myocardial [123I] metaiodobenzylguanidine uptake. The cortical FBB-binding pattern in all subjects, including APOE e4 carriers, suggested negative Aβ deposition.

CONCLUSION

Patients with PD without dementia exhibit an extremely low prevalence of Aβ positivity compared with those reported in cognitively normal elderly controls. Further longitudinal imaging studies and long-term follow-up are needed; however, our findings provide novel insights for understanding Aβ metabolism in PD.

摘要

背景

大多数路易体痴呆(DLB)病例显示出类似阿尔茨海默病病理的老年斑和神经原纤维缠结。多项研究还揭示,DLB中淀粉样蛋白正电子发射断层扫描(PET)成像阳性的患病率较高,而帕金森病(PD)合并痴呆的患者中该患病率为中等。然而,在无痴呆的PD患者中,脑β淀粉样蛋白(Aβ)负担何时开始及进展尚不清楚。我们的研究旨在使用淀粉样蛋白PET确定无痴呆的PD患者中Aβ沉积的患病率。

方法

这是一项针对33例无痴呆的PD患者的横断面研究,其中21例认知正常,12例符合PD-轻度认知障碍标准。所有受试者均接受神经心理学评估和[18F]氟比他班(FBB)PET检查。

结果

所有受试者均患有路易体相关疾病,心肌[123I]间碘苄胍摄取显著降低。所有受试者(包括APOE e4携带者)的皮质FBB结合模式均提示Aβ沉积为阴性。

结论

与认知正常的老年对照者相比,无痴呆的PD患者Aβ阳性的患病率极低。需要进一步的纵向影像学研究和长期随访;然而,我们的发现为理解PD中的Aβ代谢提供了新的见解。

相似文献

1
Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia.无痴呆帕金森病患者中淀粉样蛋白正电子发射断层扫描阳性的极低患病率
Eur Neurol. 2017;77(5-6):231-237. doi: 10.1159/000464322. Epub 2017 Mar 11.
2
Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.路易体病中淀粉样蛋白依赖性 tau 积累的不同模式。
Mov Disord. 2018 Feb;33(2):262-272. doi: 10.1002/mds.27252. Epub 2017 Nov 23.
3
Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.帕金森病中的淀粉样蛋白沉积与认知障碍:一项系统综述。
Mov Disord. 2015 Jun;30(7):928-35. doi: 10.1002/mds.26191. Epub 2015 Apr 16.
4
Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography.正电子发射断层扫描在帕金森病痴呆和路易体痴呆中的淀粉样蛋白成像。
Mov Disord. 2009;24 Suppl 2:S742-7. doi: 10.1002/mds.22581.
5
Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.帕金森病中 tau、β-淀粉样蛋白与认知的相关性。
JAMA Neurol. 2018 Feb 1;75(2):227-235. doi: 10.1001/jamaneurol.2017.3713.
6
Amyloid PET Imaging in Lewy body disorders.路易体障碍的淀粉样 PET 成像。
Am J Geriatr Psychiatry. 2015 Jan;23(1):23-37. doi: 10.1016/j.jagp.2013.03.001. Epub 2013 Jul 3.
7
Molecular imaging of dementia.痴呆的分子影像学。
Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x.
8
Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.帕金森病中FDDNP正电子发射断层扫描(PET)与脑脊液淀粉样蛋白-β和tau蛋白的横断面及纵向认知关联1
J Alzheimers Dis. 2017;55(3):1261-1272. doi: 10.3233/JAD-160698.
9
The Association of β-Amyloid with Cognition and Striatal Dopamine in Early, Non-Demented Parkinson's Disease.早期非痴呆型帕金森病患者β-淀粉样蛋白与认知功能和纹状体多巴胺的相关性研究。
J Parkinsons Dis. 2021;11(2):605-613. doi: 10.3233/JPD-202496.
10
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.氟替卡匹尔PET tau蛋白结合与淀粉样蛋白负荷、临床诊断、年龄和认知之间的关系。
Brain. 2017 Mar 1;140(3):748-763. doi: 10.1093/brain/aww334.

引用本文的文献

1
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer's disease.用于阿尔茨海默病淀粉样蛋白β正电子发射断层显像的日本多基因风险评分模型的开发。
Alzheimers Res Ther. 2025 May 22;17(1):112. doi: 10.1186/s13195-025-01754-2.
2
The role of on cognitive impairment in Parkinson's disease and Parkinsonisms.[具体内容]对帕金森病和帕金森综合征认知障碍的作用。 需注意,原文中“on cognitive impairment”前似乎缺失了关键信息。
Front Neurosci. 2025 Feb 20;19:1515374. doi: 10.3389/fnins.2025.1515374. eCollection 2025.
3
Can the clinical sign "head-turning sign" and simple questions in "Neucop-Q" predict amyloid β pathology?
临床征象“头转向征”和“Neucop-Q”中的简单问题能否预测淀粉样β病理?
Alzheimers Res Ther. 2024 Nov 21;16(1):250. doi: 10.1186/s13195-024-01605-6.
4
Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease.路易体病患者及高危人群的神经退行性变血浆生物标志物
NPJ Parkinsons Dis. 2024 Jul 31;10(1):135. doi: 10.1038/s41531-024-00745-8.
5
Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions.神经影像学和液体生物标志物在靶向干预时代的帕金森病。
Nat Commun. 2024 Jul 5;15(1):5661. doi: 10.1038/s41467-024-49949-9.
6
Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.帕金森病认知障碍的病理生物学:挑战与展望。
Int J Mol Sci. 2023 Dec 29;25(1):498. doi: 10.3390/ijms25010498.
7
Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.帕金森病疾病修饰临床试验的结局指标:EJS ACT-PD 多臂多阶段试验倡议共识文件。
J Parkinsons Dis. 2023;13(6):1011-1033. doi: 10.3233/JPD-230051.
8
Research Evidence of the Role of the Glymphatic System and Its Potential Pharmacological Modulation in Neurodegenerative Diseases.淋巴系统在神经退行性疾病中的作用及其潜在药物调节的研究证据
J Clin Med. 2022 Nov 25;11(23):6964. doi: 10.3390/jcm11236964.
9
Findings of F-PI-2620 tau PET imaging in patients with Alzheimer's disease and healthy controls in relation to the plasma P-tau181 levels in a Japanese sample.在日本样本中,评估 F-PI-2620 tau PET 成像在阿尔茨海默病患者和健康对照者中的发现与血浆 P-tau181 水平的关系。
Neuropsychopharmacol Rep. 2022 Dec;42(4):437-448. doi: 10.1002/npr2.12281. Epub 2022 Jul 17.
10
Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease.细胞外囊泡生物标志物在帕金森病认知障碍中的应用。
Brain. 2023 Jan 5;146(1):195-208. doi: 10.1093/brain/awac258.